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Background/aim: To assess the real-life efficacy, retention rate, and safety data of tofacitinib in rheumatoid arthritis (RA) patients.
Materials and methods: We analyzed all patients registered in the HURBİO database who received at least 1 dose of tofacitinib. Patients
who received at least one dose were included in retention analysis; patients with at least 1 control visit were included in efficacy and
safety analysis. Factors predicting good response at the last follow-up visit were analyzed by logistic regression analysis. Drug retention
rates were calculated using the Kaplan–Meier method and predictors of drug retention were determined by Cox proportional hazard
model. Adverse events, reasons for switching, and discontinuation were also determined.
Results: Two hundred and forty-seven (210, 85.0% female) patients were included in the study. The median duration of tofacitinib
treatment was 10.2 (20.2) [med, (IQR)] months. Two hundred and four (82.6%) patients were included in safety and efficacy analysis;
45.6% of patients were in low-disease activity (LDA) state (DAS28-CRP ≤ 3.2). Predictors of LDA were being biologic-naïve [aOR
2.53 (1.31–4.88); 95% CI] and RF negativity [aOR 2.14 (1.12–4.07); 95% CI]. At 1 year, the overall tofacitinib retention rate was 63.9%
with no relevant predicting factor. Response and retention rates of tofacitinib were similar in patients with and without concomitant
csDMARDs. Treatment failure was the most common cause of discontinuation. The most common infectious and laboratory adverse
events were herpes zoster infection (3.9 per 100 patient-years) and elevation in ALT (x3UNL: 9.7 per 100 patient-years), respectively.
Conclusion: Tofacitinib is effective as monotherapy or in combination with csDMARDs. It is a well-tolerated treatment option in
Turkish RA patients.
Key words: Rheumatoid arthritis, tofacitinib, real-life, predictor

1. Introduction
Rheumatoid arthritis (RA) is a chronic immune-mediated
disease characterized by systemic inflammation causing
articular and extraarticular manifestations. Systemic
inflammation is directly correlated with active disease and
ongoing active disease may cause functional impairment,
reduced quality of life, organ-system dysfunction, and
even death [1]. The main principle of RA treatment is to
reach sustained remission or low disease activity (LDA) in
every patient [2].
In the last 20 years, biologic agents redesigned the
principles of RA management. Despite the growing number
of “biologic players”, there is still an unmet need in RA
management. Approximately half of the patients do not
respond sufficiently to conventional synthetic (cs) or biologic
(b) disease-modifying antirheumatic drugs (DMARD),
revealing the need for alternative treatments [3].

Tofacitinib is an oral pan-Janus kinase (JAK) inhibitor.
Phase II and III clinical trials revealed the efficacy of
tofacitinib, either as a monotherapy or in combination
with csDMARDs, in RA patients [4–7]. Comparative
studies of tofacitinib and other bDMARDs resulted in
similar efficacy and safety profiles [4,7–10]. Although the
safety and efficacy have been evaluated in clinical trials,
there is still a need for the real-life experience of tofacitinib
to confirm its role in RA management.
In this study, our primary aim was to determine the
real-life efficacy, retention rate, and safety profile of
tofacitinib in RA patients treated at our center.
2. Methods
2.1. Study population
We conducted this retrospective longitudinal analysis with
RA patients who received at least 1 dose of tofacitinib from
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March 2015 until the end of November 2019 and were
registered in the Hacettepe University biological database
(HUR-BİO) which was established in a 2005 study [11].
The diagnosis of RA was established by a treating physician
with taking into account the history, physical examination,
laboratory, and imaging of the patients. All patients met
the 1987 American College of Rheumatology (ACR) and/
or 2010 European League Against Rheumatism (EULAR)/
ACR classification criteria [12,13].
According to Turkish Social Security and Prescription
rules, patients receiving biologic/targeted-synthetic
DMARDs ought to be seen every 3 months by the treating
physician. With the aid of these regulations, many patients
are in regular follow-up and we could identify whether the
patients actually received the drug. If the patient had no
control visit for 6 months after prescription, the treating
physician made a constructed phone call with the patient
or their relatives to confirm whether the patient received
tofacitinib. A total of 275 RA patients were prescribed
tofacitinib; 28 (10.2%) of them never received the drug.
As a result, our main study population consisted of 247
patients who received at least 1 dose of tofacitinib.
2.2. Data collection
2.2.1. Demographic data and population characteristics
We collected the following demographic data: sex, age,
smoking history, body mass index (BMI), frequency of
hypertension and diabetes mellitus. Regarding RA, disease
duration rheumatoid factor (RF) and anticyclic citrullinated
peptide (anti-CCP) positivity, duration under tofacitinib,
percentage of biologic-naïve patients, distribution of
previous bDMARDs in the biologic-experienced group,
concomitant DMARD [methotrexate (MTX), leflunomide
(LEF), sulphasalazine (SLZ), hydroxychloroquine (HCQ)]
and glucocorticoid (GC) use at last visit, baseline disease
activity and functional status parameters [erythrocyte
sedimentation rate (ESR) (mm/h), C-reactive protein
(CRP) (mg/dL), tender and swollen joint count (28 joints),
patient global-visual analog scale assessment (VAS) (0–
100 mm) (PGA-VAS), disease activity score (DAS) 28ESR, and health assessment questionnaire-disability index
(HAQ-DI)] were recorded.
For the main analyses, we grouped patients as
biologic-naïve vs. biologic-experienced and tofacitinib
monotherapy vs. tofacitinib + concomitant csDMARDs.
2.2.2. Assessment of efficacy
Patients who had at least 1 control visit under tofacitinib
and complete baseline disease activity data were included
in the efficacy analysis. To test the overall effectiveness
of tofacitinib, we compared the ESR, CRP, PGA-VAS,
tender and swollen joint counts, DAS28, and HAQ-DI
scores at the visit just before starting tofacitinib and
the last visit of the patient under tofacitinib therapy. As
physician global assessment has not been recorded in
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our database, we could not compare the clinical disease
activity index (CDAI) or simple disease activity index
(SDAI) scores. Also, we had no missing values of DAS28
at the last visits of patients, so we decided to take this time
point for comparison instead of the 3rd or 6th month
of therapy and adjust the final model for the duration
of tofacitinib therapy. Patients were categorized into 4
groups according to DAS28 score at last follow-up visit:
Remission (DAS28 ≤ 2.6), low (2.6–3.2), moderate (3.3–
5.1), and high (>5.1) [14]. Patients were further grouped
as responders or nonresponders according to DAS28 at
the last follow-up visit; DAS28 ≤ 3.2: responders; DAS28
> 3.2: nonresponders. We also used the EULAR response
criteria to assess the efficacy of tofacitinib [15]. In this
assessment, patients were categorized into 3 groups: good
response (DAS28 improvement regarding baseline > 1.2
and DAS28 at last visit ≤ 3.2), moderate response (DAS28
improvement regarding baseline > 1.2 and DAS28 at last
visit > 3.2 or DAS28 improvement regarding baseline > 0.6
to ≤ 1.2 and DAS28 at last visit ≤ 5.1), and no response
(DAS28 improvement regarding baseline ≤ 0.6, irrespective
of DAS28 at last visit or DAS28 improvement regarding
baseline > 0.6 to ≤ 1.2 and DAS28 at last visit > 5.1).
Besides evaluating disease activity, HAQ-DI scores at first
and last visits (calculated for patients with baseline HAQDI score > 0.5) were compared to determine the effects of
tofacitinib on the functional status of patients. A minimal
clinical difference of HAQ-DI score has been proposed
as 0.22 (calculated for patients with baseline HAQ-DI
score > 0.5), and functional remission has been defined as
HAQ-DI ≤ 0.5 in earlier studies [16,17]. We defined the
percentage of patients who met these definitions.
2.2.3. Assessment of retention rate
Patients who had at least 1 dose of tofacitinib were
included in the drug retention analysis. To calculate the
drug retention more precisely, patients to whom tofacitinib
was prescribed and who have not had a control visit in the
following 6 months were assigned into the tofacitinibcontinue group if they had not been prescribed another
biologic treatment. If the patients have not had a control
visit for over 6 months and they had not been prescribed
tofacitinib by another institution, they were assigned into
the tofacitinib-discontinue group.
2.2.4. Tofacitinib discontinuation and adverse events
Tofacitinib discontinuation and adverse event analysis was
done on patients who had at least 1 control visit under
tofacitinib and complete baseline data. Discontinuation
rates and causes of discontinuation were analyzed for
biologic-naïve and experienced groups.
For safety reasons, adverse events attributable to
tofacitinib (neutropenia (<1500/mm3), leukopenia
(<4000/mm3), transaminitis [alanine aminotransferase
(ALT) > 3 X UNL (upper normal limit, UNL = 40 IU/
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mL)], changes in lipid profile (calculated for patients
who had baseline and follow-up values), herpes zoster
(HZ) infection and infections other than HZ, hepatitis
reactivation, tuberculosis, cancer) were analyzed. Adverse
events other than laboratory abnormalities were calculated
per 100 patient-years.
2.3. Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences software (version 25.0;
IBM Corporation, Armonk, NY, USA). The variables were
investigated using visual (histogram, probability plots)
and analytic methods (Kolmogorov–Smirnov, skewness,
and kurtosis) to determine whether they are normally
distributed or not. The data of descriptive analysis were
expressed as either mean ± standard deviation (SD) or the
median, interquartile range (IQR). Categorical variables
were compared with the chi-square test or Fisher’s exact
test where appropriate. Student’s t-test and Mann–
Whitney U test were used to compare the normally and
nonnormally distributed continuous data between the two
groups, respectively.
The univariate effects of age, sex, disease duration,
smoking history, BMI, history of biologic treatment,
RF and CCP positivity, baseline ESR-CRP levels, the
status of concomitant DMARD, and glucocorticoid use
identified with univariate analyzes (P < 0.20) were further
entered into the logistic regression analysis to determine
independent predictors of remission or low disease activity
based on DAS28 at last follow-up visit. The same method
was also used to determine independent predictors of
good EULAR response at the last follow-up visit. Hosmer–
Lemeshow goodness-of-fit statistics were used to assess
model fit.
Possible factors (same factors tested for remission
or low disease activity) on tofacitinib retention were
investigated using the log-rank test. Kaplan–Meier survival
estimates were calculated. Possible factors identified
with univariate analyses (P < 0.20) were further entered
into the Cox regression analysis with backward selection
to determine independent predictors of tofacitinib
retention. Among correlated factors with similar effects on
tofacitinib retention, only those with clinical significance
were included. The proportional hazards assumption and
model fit were assessed by means of residual (Schonfeld
and Martingale) analysis.
Adverse events other than the lipid profile were
estimated for 100 patient-years.
A 5% type-I error
level was used to infer statistical significance.
3. Results
3.1. Study population and patient characteristics
A total of 247 patients were included in the study. The
mean age was 53.1 ± 12.6 years and 210 (85.0%) patients

were female. The mean disease duration was 11.4 ± 8.0
years. The current smoking ratio was 25.5%. Hypertension,
diabetes mellitus, and obesity (BMI > 30) were prevalent in
30.1%, 13.0%, 47.0% of patients, respectively. RF, antiCCP,
RF and/or anti-CCP positivity rates were 66.7%, 65.2%,
and 79.7%, respectively. The rate of concomitant synthetic
DMARD and GC use and disease activity parameters at
the first visit were similar between biologic-naïve and
biologic-experienced groups (Table 1).
Overall, 137 (55.5%) patients were bDMARD-naïve.
In bDMARD-experienced group (n = 110, 44.5%), the
number of previous bDMARDs was [med, (IQR)] 3 (2–4).
Of 110 patients, 44 (40.0%) had only anti-TNF, 23 (20.9%)
had only nonanti-TNF, and 43 (39.1%) had at least one
anti-TNF and nonanti-TNF bDMARDs before tofacitinib.
Distribution of former bDMARD therapies: 59 (53.6%)
adalimumab, 51 (46.4%) etanercept, 45 (40.9%) abatacept,
41 (37.3%) tocilizumab, 27 (24.5%) certolizumab, 23
(20.9%) rituximab, 21 (19.1%) infliximab, and 15 (16.6%)
golimumab.
3.2. Tofacitinib efficacy and retention rate
3.2.1. Efficacy
Of 247 patients, 27 (10.9%) had missing first visit data
and 16 (6.5%) did not have a first control visit yet by the
date of data analysis. Patients with at least one control
visit after starting tofacitinib and complete baseline data
(204, 82.6%) were included in further analyses to compare
the effectiveness of the drug (see Figure 1). The median
follow-up of these patients when they have been receiving
tofacitinib was 11.6 (20.7) [med, (IQR)] months. Baseline
vs. last follow-up visit values for these parameters were as
follows: ESR: 28 (29) vs. 22 (22); CRP: 1.2 (1.6) vs. 0.6 (0.8);
SJC: 2 (4) vs. 0 (2); TJC: 5 (7) vs. 1 (5); PGA-VAS: 70 (30)
vs. 50 (30); DAS28: 4.7 ± 1.4 vs. 3.6 ± 1.5; HAQ-DI: 1.02
(1.10) vs. 0.65 (1.01); P < 0.001 for all parameters.
The distribution of patients into DAS28 categories
(remission, low, moderate, high) was 26.0%, 19.6%, 37.3%,
and 17.2%, respectively. The percentage of patients fitting
into different disease activity categories according to
their concomitant DMARD use [monotherapy (±GCs)
vs. combination] were similar. The details of patients’
distribution are given in Figure 2.
Overall, 45.6% of patients were in the “responders”
group and 54.4% of patients were in the “nonresponders”
group. Predictors of response (DAS28-CRP ≤ 3.2 at last
follow-up visit) were determined by logistic regression
analysis. Predictors of good response to tofacitinib were
(in multivariate analysis, adjusted for follow-up duration
under tofacitinib, RA disease duration, and baseline DAS28
score): being biologic-naïve [OR 2.53 (1.31–4.88); 95% CI]
and RF negativity [OR 2.14 (1.12–4.07); 95% CI] (Table 2).
Model fit was tested by the Hosmer–Lemeshow test (P =
0.46). Response (DAS28-CRP ≤ 3.2) rates were 53.3% vs.
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Table 1. Demographic and baseline disease characteristics of all patients, comparison of these variables among biologic-naïve and
experienced patients.
Variables*

All patients
(n = 247)

Biologic-naïve
(n = 137, 55.5%)

Biologic-experienced
(n = 110, 44.5%)

P

Female

210 (85.0)

116 (84.7)

94 (85.5)

0.86

Age, years (mean ± SD)

53.1 ± 12.6

53.7 ± 12.9

52.3 ± 12.3

0.37

Disease duration, years (mean ± SD)

11.4 ± 8.0

9.5 ± 7.5

13.6 ± 8.0

<0.001

Smoking
- Current smoker
- Ex-smoker or never smoked

63 (25.5)
184 (74.5)

31 (22.6)
106 (77.4)

32 (29.1)
78 (70.9)

0.24

BMI ≥ 30

116 (47.0)

63 (46.0)

Hypertension

74 (30.1)

38 (27.7)

36 (33.0)

0.36

Diabetes

32 (13.0)

17 (12.4)

15 (13.8)

0.75

Positive RF (n=240)

160 (66.7)

93 (69.4)

67 (63.2)

0.31

Positive CCP (n=207)

135 (65.2)

81 (71.1)

54 (58.1)

0.06

Positive RF or CCP (n=236)

188 (79.7)

111 (83.5)

77 (74.8)

0.10

Duration under Tofacitinib, months (med, IQR)

10.2 (20.2)

10.9 (19.8)

9.5 (16.5)

0.13

Monotherapy (±GC) (at last visit)

41 (16.6)

21 (15.3)

20 (18.2)

0.55

Glucocorticoids (at last visit)

182 (73.7)

106 (77.4)

76 (69.1)

0.15

206 (83.4)

116 (84.7)

90 (81.8)

0.54

61 (24.7)
70 (28.9)
9 (3.7)
135 (55.8)

35 (25.5)
32 (23.4)
4 (2.9)
83 (60.6)

26 (23.6)
38 (34.5)
5 (4.5)
52 (47.3)

0.72
0.07
0.49
0.04

27 (28)
1.3 (1.5)
4 (7)
2 (4)
70 (30)
4.7 ± 1.4
1.05 (1.15)

26 (27)
1.2 (1.4)
4 (6)
2 (4)
70 (30)
4.6 ± 1.4
0.95 (1.10)

28 (30)
1.3 (1.6)
4 (7)
2 (4)
70 (30)
4.6 ± 1.3
1.15 (1.05)

0.91
0.56
0.64
0.74
0.75
0.86
0.07

Combination with at least one csDMARD (at last visit)
- Methotrexate
- Leflunomide
- Sulphasalazine
- Hydroxychloroquine
Disease activity (at first visit) (n=220)
- ESR
- CRP
- Tender joint count
- Swollen joint count
- Patient VAS global
- DAS28
- HAQ

53 (48.2)

0.73

* n (%), if otherwise specified.
BMI: body mass index, CCP: cyclic-citrulinated peptide, csDMARD: conventional synthetic disease modifying antirheumatic drugs,
CRP: C-reactive protein, DAS28: disease activity score 28, ESR: erythrocyte sedimentation rate, GC: glucocorticoids, HAQ: health
assessment questionnaire, IQR: interquartile range, RF: rheumatoid factor, TOFA: tofaacitinib, VAS: visual analogue scale.

34.5% in biologic-naïve and biologic-experienced patients,
respectively; 56.9% vs. 40.4% in RF negative and RF positive
patients, respectively. Anti-CCP status or seropositivity
status (RF and/or anti-CCP positivity or absence of both)
were statistically insignificant when they were entered into
the model one by one instead of RF status.
According to EULAR response criteria, 45.6%, 22.1%,
and 32.4% of patients met the good, moderate, and no
response criteria, respectively, at the last follow-up visit.
Predictors of good EULAR response criteria were (in
multivariate analysis, adjusted for follow-up duration
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under tofacitinib, RA disease duration, and baseline
DAS28 score): being biologic-naïve [OR 2.70 (1.40–5.25);
95% CI] and RF negativity [OR 2.17 (1.13–4.16); 95%
CI]. Anti-CCP status or seropositivity status (RF and/or
anti-CCP positivity or absence of both) were statistically
insignificant when they entered into the model one by one
instead of RF status. Model fit was tested by the Hosmer–
Lemeshow test (P = 0.30).
At the first visit, 26% of patients had a HAQ-DI score
≤ 0.5, while 45% of patients had a HAQ-DI score ≤ 0.5 at
the last follow-up visit (P < 0.001). The mean difference
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TOFA prescribed
n= 275

Never received TOFA
n=28 (10.1%)

Patients ever received
TOFA
n=247 (100%)
Patients with missing first visit data:
n=27 (10.9%)
Patients without first control visit :
n=16 (6.5%)
Patients with at least
1 control visit
n=204 (82.6%)
Median follow-up: 12.7 (5.5-26.2)

Median follow-up: 11.1 (4.2-25.4)
Biologicexperienced
n=84 (41.2%)

Biologic- naive
n=120 (58.8%)

74 (61.7%)
patients
continued
TOFA

46 (39.3%) patients discontinued TOFA
33 (27.5%)  switched to another
biologic
13 (10.85)  discontinued
permenantly

- Primary failure: 17 (36.9)
- Secondary failure: 10 (21.9)
- Patients preference: 8 (17.5)
- Adverse events: 5 (10.8)
- Allergic reaction/rash: 2 (4.3)
- Coronary artery disease: 1 (2.1)
- Gastrointestinal bleeding: 1 (2.1)
- Knee prosthesis infection: 1 (2.1)
- Unknown: 3 (6.5)
- Deescalation to csDMARDs: 2 (4.3)
- Pregnancy plan: 1 (2.1)

44 (52.3%)
patients
continued with
TOFA

40 (47.6%) patients discontinued TOFA
34 (40.4%)  switched to another
biologic
6 (7.2%)  discontinued
permenantly

- Primary failure: 13 (32.5)
- Secondary failure: 7 (17.5)
- Adverse events: 8 (20.0)
- Allergic reaction/rash: 4 (10)
- Leukopenia: 1 (2.5)
- Urinary tract infection: 1 (2.5)
- Herpes: 1 (2.5)
- Pneumonia: 1 (2.5)
- Unknown: 6 (15.0)
- Patients’ preference: 5 (12.5)
- Pregnancy: 1 (2.5)

Figure 1. Flow chart of patient enrollment, causes of discontinuation.

of HAQ-DI scores and HAQ-DI drop ≥ 0.22 at the last
follow-up visit compared to the first visit were calculated
for 150 (74%) patients who had a baseline HAQ-DI score
> 0.5. The mean difference was 0.40 (95% CI, 0.30–0.40, P
< 0.001) and HAQ-DI decrease ≥ 0.22 was valid for 83/150
(55.3%) patients.

3.2.2. Retention
The tofacitinib retention rate was calculated over the
whole study population (n = 247, 100%). The median
duration of tofacitinib treatment was 10.2 (20.2) [med,
(IQR)] months and similar among biologic-naïve and
biologic-experienced groups. At 1 year, the overall
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Figure 2. Percentages of patients in four DAS28 categories according to DAS28 score at last follow-up visit. The left side represents
the overall group, the right side represents data according to concomitant csDMARD use at the last follow-up visit (tofacitinib ±
glucocorticoids vs. tofacitinib + DMARDs ± glucocorticoids).

tofacitinib retention rate was 63.9% (Figure 3A). The
median tofacitinib retention was 24.9 (16) [med, (IQR)]
months. Unadjusted tofacitinib retention rates were
similar in patients receiving tofacitinib as monotherapy
(±GCs) or combination with DMARDs (1-year retention:
monotherapy (±GCs) vs. combination: 59.7% vs. 64.8%,
P = 0.76, Figure 3B). Unadjusted tofacitinib retention
rates were similar in bDMARD-naïve and experienced
patients (1-year retention: bDMARD-naïve vs. bDMARDexperienced: 59.6% vs. 65.2%, P = 0.26, Figure 3C).
In multivariate analysis, we found no relevant factor
predicting better tofacitinib retention.
3.3.3. Tofacitinib discontinuation and adverse events
attributable to tofacitinib
Tofacitinib was discontinued in 86 (42.2%) of 204
patients; discontinuation rates were similar for biologicnaïve and biologic-experienced groups (38.3% vs. 47.7%,
respectively; P = 0.23, log-rank). Treatment failure
(primary and secondary) was the most common cause of
discontinuation and seen at similar rates among biologicnaïve and biologic-experienced groups (primary: 36.9% vs.
32.5%; secondary: 21.9 vs. 17.5%; total: 58.8% vs. 50.0%,
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respectively). Rates of adverse events causing treatment
discontinuation were 10.8% and 20% among biologicnaïve and experienced groups, respectively, and the
difference was not statistically significant (P = 0.28). These
adverse events were; in the biologic-naïve group: 2 allergic
skin reactions, 1 coronary artery disease, 1 gastrointestinal
bleeding, 1 knee prosthesis infection; and in the biologicexperienced group: 4 allergic skin reactions, 1 urinary tract
infection, 1 pneumonia, 1 leukopenia, 1 herpes zoster. The
details of the therapy switch are given in Figure 1.
The most common laboratory abnormality during
the treatment course was an elevation in ALT (>3xUNL:
9.7 per 100 patient-years). Leukopenia was prevalent in
2% of patients, severe leukopenia causing drug cessation
was seen in 1 patient. Neutropenia was seen in 0.5% of
patients and it was not severe enough to cause tofacitinib
cessation. A lipid profile at the beginning of tofacitinib
administration and at the last follow-up visit under
tofacitinib was available for 37 patients. HDL levels were
higher at the last follow-up visit compared to the beginning
of the tofacitinib regimen at significant levels (P = 0.03);
LDL, total cholesterol, and triglyceride levels were similar.
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Table 2. Predictors of good response* to tofacitinib.
Univariate analysis

Multivariate analysis †,‡

Final multivariate model†,¶

Odds ratio
(95% CI)

P value

Adjusted odds ratio
(95% CI)

P value

Adjusted odds ratio
(95% CI)

P value

Sex
(female vs. male)

1.98 (0.90–4.36)

0.11

1.42 (0.57–3.58)

0.44

Smoking
(current vs. ex-never)

0.97 (0.51–1.84)

0.93

BMI
(>25 vs. <25)

1.27 (0.66–2.41)

0.46

History of biologic treatment
(naïve vs. experienced)

2.17 (1.22–3.85)

0.008

2.44 (1.22–4.87)

0.011

2.53 (1.31–4.88)

0.005

Rheumatoid factor
(negative vs. positive)

1.94 (1.07–3.54)

0.03

1.89 (0.97–3.70)

0.062

2.14 (1.12–4.07)

0.021

Anti-CCP antibody
(negative vs. positive)

1.41 (0.74–2.67)

0.29

Baseline ESR
(>20 mm/h vs. normal)

0.61 (0.33–1.12)

0.12

0.87 (0.42–1.83)

0.73

Baseline C-reactive protein
(>0.8 mg/dL vs. normal)

0.74 (0.41–1.35)

0.33

Concomitant csDMARD
(yes vs. no)

1.04 (0.51–2.11)

0.90

*Good response means DAS28 ≤ 3.2 at last follow-up visit.
†
Adjusted for follow-up duration under tofacitinib, RA disease duration and baseline DAS28 score;
‡
Variables with P < 0.20 in univariate analyses were included. This is the baseline model.
¶
Logistic regression with backward LR.

Incidence rates for herpes zoster and other infections
were 3.9 (11 patients) and 1.4 (4 patients) per 100 patientyears, respectively. All HZ cases were monophasic, and
one of 11 (9.1%) patients discontinued tofacitinib. Three
of 4 patients who had hospitalization-requiring infections
discontinued tofacitinib. Details of adverse events that can
be attributed to tofacitinib are given in Table 3.
4. Discussion
In this study, we reported the real-life efficacy, drug
retention, and safety of tofacitinib in Turkish RA patients.
Low disease activity (DAS28 ≤ 3.2) was achieved in 45.6%
of patients at the last follow-up visit. Being biologic-naïve
and the absence of RF were independent predictors of low
disease activity. At 1 year, the overall tofacitinib retention
rate was 63.9%. Disease activity at the last follow-up visit
and tofacitinib retention were similar in patients receiving
tofacitinib as monotherapy or in combination with
csDMARDs. The rate and distribution of adverse events
were similar to the current literature.

Real-life data on JAK kinase inhibitors such as
tofacitinib in RA is growing. Remission and LDA with
tofacitinib have been studied extensively in clinical trials
[4,10,18–20]. Long-term extension (LTE) studies of
phase-3 randomized clinical trials of tofacitinib make up
the main body of real-life tofacitinib evidence. One of the
largest LTE studies was the ORAL Sequel LTE study that
included 4290 patients. In this study, the LDA (DAS28
≤ 3.2) rate was 46.8% at the end of the 96th month [21].
In a recent study from Switzerland, low-disease activity
(DAS28 ≤ 3.2) was achieved by 58.2% of 144 RA patients
on tofacitinib after a 1.2-year follow-up [22]. These data
are in line with our study and the efficacy of tofacitinib was
also demonstrated in small observational studies [23–25].
Besides its efficacy on disease activity, it was also shown
in clinical trials that tofacitinib improves the functional
status of RA patients. In the present study, the mean HAQDI difference was 0.40, HAQ-DI decrease ≥ 0.22 was
valid for 55.3% of patients. These improvements were in
parallel with the LTE studies of tofacitinib [21]. We found
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Figure 3. Retention analysis of tofacitinib (by Kaplan–Meier and log-rank comparison). A) Unadjusted tofacitinib retention
in rheumatoid arthritis patients; B) Unadjusted tofacitinib retention according to concomitant csDMARD use (tofacitinib
± glucocorticoids vs. tofacitinib + DMARDs ± glucocorticoids); C) Unadjusted tofacitinib retention according to concomitant
previous biologic DMARD use.

that being biologic-naïve and the absence of rheumatoid
factor were independent predictors of good response to
tofacitinib after adjusting for disease duration and baseline
disease activity. Previous biologic agent use had 4.5 times
higher risk of nonresponse to tofacitinib in a prospective
observational study from Japan including 113 RA patients
[26]; a similar association was also demonstrated by
different studies [22]. The effects of serologic status on
the treatment outcomes have been studied in LTE studies
of tofacitinib RCTs. In that analysis, response rates were
higher in seropositive patients compared to seronegative
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patients (response rates: anti-CCP+/RF+ > anti-CCP–/
RF–, anti-CCP+/RF– > anti-CCP–/RF–, anti-CCP–/
RF+ > anti-CCP–/RF–) [27]. However, this association
has not been fully confirmed by real-life data. Similar to
our study, there was no difference in anti-CCP positivity
among responders and nonresponders in studies by Mori,
Iwamoto, Mueller, and colleagues. Mori et al. did not report
RF status; the others reported no relationship between
RF status and response rates [19,22,26]. Also, there are
conflicting data regarding the RF status and response
to TNF inhibitors. Some of these studies suggested that
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Table 3. Adverse events attributable to tofacitinib.
Adverse Events

Value

Leukopenia (<4000 / mm )*

5.7

Neutropenia (<1500 / mm ) *

1.4

ALT > 3 X UNL*

9.7

Lipid profile (med, Q1-4) (n = 37)

Pre

- Total cholesterol

213 (192–243)

232 (193–261)

0.10

- LDL

138 (123–156)

145 (120–167)

0.12

- HDL

57 (46–71)

64 (53–73)

0.03

- Triglyceride

129 (99–187)

136 (104–177)

0.46

Allergic reactions/rash*

3.2

Herpes Zoster*

3.9

Tuberculosis*

0

3

3

HBV reactivation*

0

Other infections*

1.4

Diverticulitis*

0

Cancer*

0

†

Post

P

*per 100 patient-years
†
Requires hospitalization: 2 pneumonia, 1 knee prosthesis infection, 1 urinary tract infection
ALT: alanine aminotransferase, HBV: hepatitis B virus, HDL: high-density lipoprotein, LDL:
low- density lipoprotein, UNL: upper normal limit.

RF positivity is a risk factor for poor response to TNF
inhibitors [28–32]. Data regarding the link between
serologic status and response to tofacitinib is scant and
conflicting. Further studies are needed to enlighten the
mechanism and clinical application of this link.
Overall tofacitinib retention rate at 1 year was 63.9%.
This rate was similar across other tofacitinib real-life data
[22,25], however, slightly lower than the retention rate of
anti-TNF agents [33]. For tofacitinib, being a late player
in the field of RA may be an explanation of this reduced
retention. However, when anti-TNF agents were compared
with tofacitinib when all the treatments were started in
the same time period, retention rates were similar. Even
higher for tofacitinib when the adjustments for potential
confounders were done [25]. We found no predictor
of better tofacitinib retention, including the status of
previous biologic DMARD use and using tofacitinib
as monotherapy or in combination with csDMARDs.
However, real-life data from Israel reported an inverse
relationship between the number of previous bDMARDs
and tofacitinib retention similar to anti-TNF agents and
they found no other relevant factors [34,35].
We found similar response and retention rates of
tofacitinib in patients with and without concomitant
csDMARDs. There are many studies demonstrating the
efficacy and safety of tofacitinib monotherapy. The ORAL

Solo trial showed the efficacy of tofacitinib monotherapy in
reducing RA signs and symptoms and improving physical
function in patients with inadequate response to diseasemodifying drugs [5]. In ORAL Standard trial, tofacitinib
add-on to methotrexate was superior to adalimumab
add-on to methotrexate therapy [8]. The results of ORAL
Strategy trial for tofacitinib monotherapy were defined
as statistically inconclusive because noninferiority of
tofacitinib 5 mg b.i.d. to either adalimumab and MTX or
tofacitinib and MTX was not shown [10]. Concomitant
csDMARDs were found to be required for optimal
treatment results for TNFi but not for tofacitinib and
non-TNFi in SCQM cohort [25]. A systematic review
and metaanalyses showed that tofacitinib monotherapy
was neither statistically nor clinically different from TNF
inhibitors in efficacy [36,37]. In addition, we noticed
that our csDMARD strategies were different from the
literature. Leflunomide (LEF) and hydroxychloroquine
(HCQ) utilization rates were higher in the present data. For
instance, Mueller and colleagues reported LEF and HCQ
rates were 17.3% and 7.6%, respectively, in their cohort
[22]. Also, participants of ORAL Solo trial were allowed to
use HCQ, and the rate was 18.5% [5]. Although the cohort
was relatively small to conclude it, LEF seems an important
player just behind MTX. Also, further assessments are
needed if there was a possible cardiovascular protective
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contribution of HCQ to neutralize cardiovascular adverse
effects. Prospective, large-scale studies are needed to reveal
these important points.
A total of 23% of our patients discontinued tofacitinib
due to ineffectiveness. Clinical trials or their LTE
studies did not report clearly on this issue. Recent reallife data reported the drug discontinuation rate due to
ineffectiveness as 15.9% [22]. This rate is a bit lower
than ours, however, the differences between these two
cohorts regarding demographics, disease, and treatment
characteristics may explain this discrepancy.
The safety profile, including infections and laboratory
anomalies, of our cohort, is consistent with the current
literature [21,22,38,39]. We had no HBV reactivation and
tuberculosis, which may be due to the strict surveillance
and prophylaxis regimen of Turkey. None of the patients
had a cancer diagnosis under tofacitinib, however, the
follow-up duration was not enough to make a decision.
Herpes zoster was the most common infection in our
cohort. We found an HZ incidence rate similar to that
reported from the USA and global data; however, we
found a lower incidence rate than reported from far East
Asia [38]. Most patients had HZ in only one dermatome
(92%), and 8% of patients with HZ discontinued tofacitinib
permanently, similar to the current study [21,40].
The main limitation of our study was its one-center
design. Our results should be validated in larger and

multicenter studies. We could not test the cardiovascular
risk of tofacitinib properly. Besides, we did not examine
the effect of tofacitinib on radiographic progression.
Also, as we could not clearly assess the drug compliance
of the patients (e.g., we accepted the patients with control
visit within 6 months in “tofacitinib-continue group” but
the patients might step-down to csDMARDs without
informing the treating physician, or patients might use
the drug irregularly) and these issues may cause under/
overestimation of drug retention. However, a 3-month
regular follow-up regulation of our social security system
has minimized the bias caused by the 6-month cut-off.
In conclusion, tofacitinib is effective as monotherapy
or in combination with csDMARDs and is a well-tolerated
treatment option in Turkish RA patients. The safety profile
is consistent with current literature.
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